Table 1.
Pancreatic tumor incidence, multiplicity and metastasis
| Treatment | Incidence (%) | Incidence, T ≥ 500 mm3 (%) | Multiplicity | Metastasis (%) | Liver met (%) | Lung met (%) |
|---|---|---|---|---|---|---|
| Placebo |
14/14 (100%) |
11/14 (78%) |
27/14 = 1.9 |
7/14 (50%) |
6/14 (43%) |
3/14 (21%) |
| DMAPT |
11/15 (73%) |
8/11 (73%) |
18/15 = 1.2 |
5/11 (45%) |
2/11 (18%) |
5/11 (45%) |
| Gemcitabine |
6/14 (43%)* |
2/6 (33%) |
6/14 = 0.4* |
3/6 (50%) |
3/6 (50%) |
1/6 (17%) |
| DMAPT/gemcitabine | 9/15 (60%)* | 1/9 (11%)* | 10/15 = 0.7* | 2/9 (22%) | 0/9 (0%)*/** | 2/9 (22%) |
Incidence = number of mice with tumors/total number of mice (n).
Incidence, T ≥ 500 mm3 = number of mice with tumor volume ≥ 500 mm3/number of tumor-bearing mice.
Multiplicity = number of tumors/total number of mice (n).
Metastasis = number of mice with metastases/number of tumor-bearing mice.
Liver Met = number of mice with liver metastases/number of tumor-bearing mice.
Lung Met = number of mice with lung metastases/number of tumor-bearing mice.
*P < 0.05 compared to placebo.
** P < 0.05 compared to gemcitabine.